Observational studyClinical oral investigations2026
Biological and clinical responses to dense and expanded PTFE membranes in alveolar ridge preservation: A prospective non-randomized cohort study with ex vivo analyses.
Observational study in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design and applications of barrier membranes for guided bone regeneration.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesNonresorbable polytetrafluoroethylene (PTFE) membranes, including dense (d-PTFE) and expanded (e-PTFE) types, are commonly utilized in alveolar ridge preservation (ARP). However, their differential effects on clinical healing remain unclear. This observational ex vivo and clinical study aimed to compare inflammatory and regenerative responses of cells adhering to retrieved d-PTFE and e-PTFE membranes and to link these responses to clinical outcomes. MATERIALS AND
methodsExpanded and dense PTFE membranes, routinely retrieved from ARP-treated patients, were cultured ex vivo under inflammatory and regenerative conditions. We measured cell viability and cytokine levels (TGF-β and IL-6) using cell counting and ELISA. Clinical wound healing was assessed three weeks post-surgery, and bone preservation was evaluated radiographically three months post-ARP.
resultsCells adherent to d-PTFE showed higher viability, lower secretion of inflammatory cytokine IL-6, and higher levels of regenerative factor TGF-β compared to e-PTFE. Clinically, d-PTFE was associated with superior soft tissue healing scores and fewer inflammatory signs. Both membrane types effectively preserved bone, though e-PTFE demonstrated a trend toward better maintenance of crestal bone.
conclusiond-PTFE membranes appear superior to e-PTFE in reducing early soft tissue inflammation and enhancing healing during ARP. However, both membranes are similarly effective at bone maintenance. Further studies with longer follow-up are warranted. CLINICAL RELEVANCE: The present findings highlight the translational potential of membrane selection in clinical practice, suggesting that clinicians can leverage each membrane's unique biologic effects to meet specific treatment objectives.
Indexed as
Identifiers
41721158What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.